Hemophilia: Diagnostic and Therapeutic Approach. A Literature Review

Authors

  • Lina María Martínez Sánchez Universidad Pontificia Bolivariana https://orcid.org/0000-0002-9555-0843
  • Luis Felipe Álvarez Hernández Universidad Pontificia Bolivariana
  • Camilo Ruiz Mejía Universidad Pontificia Bolivariana
  • Laura Isabel Jaramillo Jaramillo Universidad Pontificia Bolivariana
  • Luz Natalia Builes Restrepo Hospital Pablo Tobón Uribe
  • Juan Diego Villegas Álzate Universidad Pontificia Bolivariana

DOI:

https://doi.org/10.17533/udea.rfnsp.v36n2a11

Keywords:

blood clotting disorders, hemophilia A, hemophilia B, genetics, coagulation factors

Abstract

Background: Hemophilia is a genetic, recessive disorder linked to the X chromosome. Its main clinical symptom is hemorrhage, whose degree depends on the level of factor VIII or IX found in plasma, usually following traumas in deep sites, such as joints, muscles and central nervous system. Objective: The objective is to present a clear and practical literature review of hemophilia, with general aspects of its pathophysiology, diagnosis and treatment, as well as the new therapeutic alternatives being developed for its treatment. Methodology: the PubMed, ScienceDirect and Scielo databases were checked, using keywords in Spanish and English. We selected 32 articles, which were the basis for constructing this text. Results: a bibliographic review including basic and practical concepts for the approach and treatment of hemophilia was constructed.
Conclusion: hemophilia is a potentially deadly disorder, affecting the quality of life of patients and those
around them as finding a proper approach for its diagnosis and treatment is challenging.
|Abstract
= 4162 veces | PDF (ESPAÑOL (ESPAÑA))
= 1729 veces|

Downloads

Download data is not yet available.

Author Biographies

Lina María Martínez Sánchez, Universidad Pontificia Bolivariana

Master in Education. Universidad Pontificia Bolivariana. Colombia.

Luis Felipe Álvarez Hernández, Universidad Pontificia Bolivariana

Medical student VII Semester. Universidad Pontificia Bolivariana. Colombia.

Camilo Ruiz Mejía, Universidad Pontificia Bolivariana

Medical student X Semester. Universidad Pontificia Bolivariana. Colombia.

Laura Isabel Jaramillo Jaramillo, Universidad Pontificia Bolivariana

Medical student XI Semester. Universidad Pontificia Bolivariana, Colombia.

Luz Natalia Builes Restrepo, Hospital Pablo Tobón Uribe

Pediatric hematologist. Hospital Pablo Tobón Uribe. Colombia.

Juan Diego Villegas Álzate, Universidad Pontificia Bolivariana

Medical Student VIII Semester. Universidad Pontificia Bolivariana. Colombia.

References

(1). García-Chavez J, Majluf-Cruz. Hemofilia. Gac. Med. Mex. 2013;149(3):308-21.

(2). De la Corte-Rodriguez H, Rodriguez-Merchan EC. The Health Assessment Questionnaire Disability Index (HAQ-DI) as a valid alternative for measuring the functional capacity of people with haemophilia. Thromb. Res. 2017;153:51-56. DOI: 10.1016/j.thromres.2017.03.016.

(3). Carcao MD. The diagnosis and management of congenital hemophilia. Semin. Thromb. Hemost. 2012;38(7):727-34. DOI: 10.1055/s-0032-1326786.

(4). Mistry T, Dogra N, Chauhan K, Shahani J. Perioperative considerations in a patient with hemophilia A: A case report and review of literature. Anesth. Essays. Res. 2017;11(1):243-5. DOI: 10.4103/0259-1162.181432.

(5). Castillo-González D. Hemofilia: aspectos históricos y genéticos. Rev. Cubana Hematol. Inmunol. 2012;28(1):22-33.

(6). Senapati SB, Mishra SS, Dhir MK, Das S. Intracerebellar haemorrage in a haemophilia child. Asian J Neurosurg. 2016;11(2):179. DOI: 10.4103/1793-5482.145059.

(7). Morales-Machín A, Borjas-Fajardo L, Zabala W, Álvarez F, Fernández E, Zambrano M, et al. Diagnóstico prenatal molecular indirecto de Hemofilia A y B. Invest Clin. 2008;49(3):289-97.

(8). Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world.Haemophilia. 2010;16(1):20-32. DOI: 10.1111/j.1365-2516.2009.02127.x.

(9). World Federation of Hemophilia. Report on the annual global survey 2016 [internet]. Montreal, Quebec: World Federation of Hemophilia; 2016 [citado 2015 ene. 23]. Disponible en: http://www1.wfh.org/publications/files/pdf-1690.pdf.

(10). Ministerio de Salud y Protección Social. Enfermedades huérfanas [internet]. s. a. [citado 2016 may. 1]. Disponible en: https://www.minsalud.gov.co/salud/publica/PENT/Paginas/enfermedades-huerfanas.aspx.

(11). Pareja, ML. Situación actual de las enfermedades huérfanas en Colombia 2017. Revista CES Derecho. 2017;2(8):231-41.

(12). Vidler V. Haemophilia: Pathophysiology and management. Nursing Times. 2003;99(41):30.

(13). Liu C, Guo J, Cui Q, Li D, Zeng Y. Clinical and imaging analysis of subclinical hemophilia combined with coxarthrosis: Case report and literature review. Springerplus. 2016;5(1):2058.

(14). Catorceno VM. Hemofilia. Rev. Act. Clin. Med. 2011;4:181-2.

(15). Kulkarni R, Soucie JM, Lusher J, Presley R, Shapiro A, Gill J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: A report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia. 2009;15(6):1281-90. DOI: 10.1111/j.1365-2516.2009.02074.x.

(16). Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost. 2010;8(3):421-32. DOI: 10.1111/j.1538-7836.2009.03717.x.

(17). Venkateswaran L, Wilimas JA, Jones DJ, Nuss R. Mild hemophilia in children: Prevalence, complications, and treatment. J Pediatr Hematol Oncol. 1998;20(1):32-5.

(18). Mantilla-Capacho J, Beltrán-Miranda C, Jaloma-Cruz A. Diagnóstico molecular en pacientes y portadoras de hemofilia A y B. Gac. Méd. Méx. 2005;141(1):69-71.

(19). Mundo-Ayala J, Jaloma-Cruz A. Evaluación del patrón de inactivación del cromosoma X en portadoras sintomáticas y mujeres con hemofilia. Gac. Méd. Méx. 2008;144(2):171-4.

(20). Lavaut K. Importancia del diagnóstico de portadoras en familias con antecedentes de hemofilia. Rev. Cubana Hematol. Inmunol. Hemoter. 2014;30(2):108-113.

(21). Ceresetto J, Duboscq C, Fondevila C, Tezanos M. Hemofilia adquirida (inhibidor adquirido del factor VIII). Medicina (Buenos Aires) 2015;75(4):231-8.

(22). Vautier M, de Boysson H, Creveuil C, Repesse Y, Borel-Derlon A, Troussard X, et al. Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study. Medicine. 2016;95:48(e5232).

(23). Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA,et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695-705. DOI: 10.1002/ajh.24777.

(24). Limperg PF, Haverman L, Beijlevelt M, van der Pot M, Zaal G, de Boer WA, et al. Psychosocial care for children with haemophilia and their parents in the Netherlands. Haemophilia. 2017;23(3):362-9. DOI: 10.1111/hae.13186.

(25). Horava SD, Peppas NA. Recent advances in hemophilia B therapy. Drug Deliv and Transl Res. 2017;7(3):1-13.

(26). Chuansumrit A, Sasanakul W, Promsonthi P, Sirachainan N, Panburana P, Kadegasem P, et al. Prenatal diagnosis for haemophilia: The Thai experience. Haemophilia. 2016;22(6):1-6.

(27). Ministerio de Salud y Protección Social, Instituto de Evaluación Tecnológica en Salud. Protocolo clínico para tratamiento con profilaxis de personas con hemofilia A severa sin inhibidores; 2015.

(28). Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: Diagnosis, treatments, and its complications. Lancet 2016;388(10040): 187-97.

(29). Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2013;1-47.

(30). Fischer K, Ljung R. Primary prophylaxis in haemophilia care: Guideline update 2016. Blood Cells Mol Dis. 2017. pii: S1079-9796(16)30282-0. DOI: 10.1016/j.bcmd.2017.03.009.

(31). Auerswald G, Dolan G, Duffy A, Hermans C, Jimenez-Yuste V, Ljung R, et al. Pain and pain management in haemophilia. Blood Coagul Fibrinolysis 2016;27(8):845-54.

(32). Hanley J, McKernan A, Creagh MD, Classey S, McLaughlin P, Goddard N, et al. Musculoskeletal Working Party of the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline. Haemophilia. 2017;23(4):511-20. DOI: 10.1111/hae.13201.

(33). Boulassel MR, Al-Ghonimi M, Al-Balushi B, Al-Naamani A, Al-Qarni Z, Wali Y, et al. Regulatory B cells are functionally impaired in patients having hemophilia A with inhibitors. Clin Appl Thromb Hemost. 2018;24(4):618-24. DOI: 10.1177/1076029617702244.

(34). Lai JD, Lillicrap D. Factor VIII inhibitors: Advances in basic and translational science. Int J Lab Hematol. 2017;39(51): Suppl 1:6-13. DOI: 10.1111/ijlh.12659.

(35). Meeks SL, Batsuli G. Hemophilia and inhibitors: Current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016;2016(1):657-62.

(36). Monahan PE, Aledort LM; Hemophilia Inhibitor Study Group. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. Am J Hematol. 2004;77(4):346-50.

(37). Nair JK, Willoughby JL, Chan A, Charisse K, Alam R, Wang Q et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958-61.

(38). Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017;377(9):819-828. DOI: 10.1056/NEJMoa1616569.

(39). Franchini M, Mannucci PM. Non-factor replacement therapy for haemophilia: A current update. Blood Transfus. 2018:1-5. DOI: 10.2450/2018.0272-17.

(40). DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology. 2006;16(9):833-43.

Downloads

Published

2018-09-06

How to Cite

1.
Martínez Sánchez LM, Álvarez Hernández LF, Ruiz Mejía C, Jaramillo Jaramillo LI, Builes Restrepo LN, Villegas Álzate JD. Hemophilia: Diagnostic and Therapeutic Approach. A Literature Review. Rev. Fac. Nac. Salud Pública [Internet]. 2018 Sep. 6 [cited 2025 Dec. 6];36(2):85-93. Available from: https://revistas.udea.edu.co/index.php/fnsp/article/view/329131

Issue

Vol. 36 No. 2 (2018): Mayo-Agosto

Section

Servicios de salud

License

The contents of the articles are the responsibility of the authors

The editorial committee has editorial independence from the National School of Public Health "Héctor Abad Gómez" of the University of Antioquia.

The editorial committee is not responsible for aspects related to copying, plagiarism or fraud that may appear in the articles published in it.

When you are going to reproduce and disclose photographs or personal data in printed or digital format, informed consent is required. Therefore, this requirement is required of the author at the time of receipt of the manuscript.

Authors are responsible for obtaining the necessary permissions to reproduce any material protected by reproduction rights.

The authors preserve the moral rights and assign the economic rights that will correspond to the University of Antioquia, to publish it, distribute electronic copies, include them in indexing services, directories or national and international databases in Open Access, under the Creative Commons Attribution license -Not Commercial-Share Equal 4.0 International Commercial (CC BY-NC-SA) which allows others to distribute, remix, retouch, and create from the work in a non-commercial way, as long as the respective credit and license are granted. new creations under the same conditions.

The authors will sign the declaration of transfer of economic rights to the University of Antioquia, after the acceptance of the manuscript.

The editorial committee reserves the right to reject the articles whose authors do not offer satisfactory explanations about the contribution of each author, to meet the criteria of authorship in the submission letter. All authors must meet the four criteria of authorship according to ICMJE: "a) .- That there is a substantial contribution to the conception or design of the article or to the acquisition, analysis or interpretation of the data. b) That they have participated in the design of the research work or in the critical review of its intellectual content. c) .- That has been intervened in the approval of the final version that will be published.d). That they have the capacity to respond to all aspects of the article in order to ensure that issues related to the accuracy or integrity of any part of the work are adequately investigated and resolved. "

Crossref
Scopus
Google Scholar
Europe PMC